ArticlePersonality disorders2015
Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samples.
Article in Personality disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effectiveness of psychosocial interventions for adults with substance use disorder that have a co-occurring mental health disorder: an umbrella review and illustrative cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2026Pooled it
- Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses.The British journal of psychiatry : the journal of mental science · 2025Pooled it
- The Generalizability of Randomized Controlled Trials of Self-Guided Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms: Systematic Review and Meta-Regression Analysis.Journal of medical Internet research · 2018Pooled it
- Toward National Estimates of Effectiveness of Treatment for Substance Use.The Journal of clinical psychiatry · 2017Trial
- Psycho-education for substance use and antisocial personality disorder: a randomized trial.BMC psychiatry · 2015Trial
- Amygdala response predicts clinical symptom reduction in patients with borderline personality disorder: A pilot fMRI study.Frontiers in behavioral neuroscience · 2022Article
- Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications.Alcohol and alcoholism (Oxford, Oxfordshire) · 2020Article
- Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies.International journal of methods in psychiatric research · 2018Article
- Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder.Pediatrics · 2017Article
- Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.Addiction (Abingdon, England) · 2017Article
- Comparison of treatment outcomes in severe personality disorder patients with or without substance use disorders: a 36-month prospective pragmatic follow-up study.Neuropsychiatric disease and treatment · 2016Article
- The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings.Social psychiatry and psychiatric epidemiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The present study sought to quantify the generalizability of clinical trial results in individuals with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of borderline personality disorder (BPD) to a large representative community sample. Data were derived from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), a large nationally representative sample of 34,653 adults from the United States population. We applied a standard set of exclusion criteria representative of pharmacological and psychotherapy clinical trials to all adults with a DSM-IV diagnosis of BPD (n = 2,231). Our aim was to assess how many participants with BPD would not fulfill typical eligibility criteria. We found that more than 7 of 10 respondents in a typical pharmacological efficacy trial and more than 5 of 10 participants in a typical psychotherapy efficacy trial would have been excluded by at least 1 criterion. Having a current history of alcohol or drug use disorder and a lifetime history of bipolar disorder explained a large proportion of ineligibility in both pharmacological and psychotherapy efficacy trials. Clinical trials should carefully consider the impact of exclusion criteria on the generalizability of their results. As required by CONSORT guidelines, reporting exclusion rate estimate and reasons of eligibility should be mandatory in both clinical trials and meta-analyses. As treatment trials of borderline personality disorder move from efficacy to effectiveness to better inform clinical practice, the eligibility rate must be increased by imposing less stringent eligibility criteria to allow for more generalizable results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.